Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. [electronic resource]
Producer: 20081008Description: 52-60 p. digitalISSN:- 0168-8278
- Angiogenesis Inhibitors -- pharmacology
- Animals
- Antibiotics, Antineoplastic -- pharmacology
- Antibodies, Monoclonal -- pharmacology
- Antibodies, Monoclonal, Humanized
- Bevacizumab
- Carcinoma, Hepatocellular -- drug therapy
- Disease Models, Animal
- Drug Therapy, Combination
- Liver Neoplasms -- drug therapy
- Mechanistic Target of Rapamycin Complex 1
- Mice
- Mice, SCID
- Multiprotein Complexes
- Proteins
- Signal Transduction -- drug effects
- Sirolimus -- pharmacology
- Survival Rate
- TOR Serine-Threonine Kinases
- Transcription Factors -- metabolism
- Vascular Endothelial Growth Factor A -- metabolism
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.